Full intensity heparin has value in treating hospitalized COVID-19 patients

Results from the RAPID clinical trial suggest heparin may lower the risk of death from moderate COVID-19 infection by 78%. Heparin also significantly increased the number of days patients went without ventilation or requiring organ support.